Cannabinoids Appear Generally Safe in Adults Over 50, But Evidence Is Limited and Heterogeneous

A 2021 systematic review and meta-analysis pooling 38 open-label and observational studies finds low adverse event rates for THC and CBD monotherapy in older adults, with higher withdrawal rates for THC:CBD combinations particularly in cancer populations, though all findings are fundamentally constrained by the absence of control groups, high heterogeneity, and diverse study designs that limit causal inference.

Why This Matters

Cannabinoid use among adults over 50 is rising steadily, driven by expanding legal access and growing patient interest in managing chronic pain, sleep disturbance, and neurodegenerative symptoms. Yet the vast majority of cannabinoid safety data come from trials enrolling younger populations, leaving clinicians without age-specific guidance for patients who may be more vulnerable to drug interactions, polypharmacy complications, and falls. This review directly addresses that evidence gap at a moment when clinicians are being asked to make cannabinoid-related decisions for older patients with limited data to guide them.

Clinical Summary

Cannabinoid prescribing in older adults has outpaced the evidence base for safety in this population, creating a clinical environment where decisions often rest on extrapolation from younger cohorts or anecdotal experience. Published in Drugs & Aging in 2021, this systematic review and meta-analysis by Velayudhan and colleagues pooled adverse event data from 38 open-label trials and observational studies enrolling 2,341 adults with a mean age of approximately 63 years. The mechanistic rationale for examining cannabinoid safety in this group is straightforward: age-related changes in hepatic metabolism, body composition, and receptor sensitivity may alter how THC and CBD are processed and tolerated, while polypharmacy increases the potential for clinically meaningful drug interactions.

The pooled analysis found that both THC monotherapy and CBD monotherapy were associated with low incidence rates of adverse events and zero serious adverse events, though confidence intervals were notably wide due to substantial heterogeneity across studies. THC:CBD combination therapy, by contrast, showed elevated rates of serious adverse events and treatment-related withdrawals, particularly in cancer populations where disease burden itself is a major confounder. Crucially, none of the 38 included studies had a control group, meaning that observed harms cannot be causally attributed to the cannabinoids rather than to underlying disease or concurrent treatments. The authors themselves emphasize that these findings complement but do not replace evidence from randomized controlled trials, and that controlled studies specifically enrolling older and frailer adults are needed before safety profiles in this population can be considered established.

Dr. Caplan’s Take

This review does something useful by focusing on older adults specifically, which is where much of the real-world clinical demand for cannabinoid guidance exists. The findings are reassuring at a surface level, showing low rates of serious harm for THC and CBD individually. But the absence of control groups in every included study is a fundamental limitation that patients and clinicians alike tend to underappreciate. When a patient over 60 comes in asking whether cannabis is “safe for people my age,” the honest answer is that we have some signal suggesting tolerability, but we lack the controlled evidence needed to separate drug effects from disease effects with any confidence.

In practice, I approach cannabinoid use in older patients with careful attention to existing medication lists, hepatic and renal function, and fall risk. I start at the lowest possible dose, titrate slowly, and monitor more frequently than I would in a younger patient. What I do not do is cite reviews like this one as evidence that cannabinoids are “proven safe” in older adults. The data simply do not support that claim, and responsible practice means being transparent about what we know and what we are still waiting to learn.

Clinical Perspective

This review sits at an early stage of the research arc for age-specific cannabinoid safety, filling a descriptive gap rather than resolving a causal question. It confirms that in uncontrolled settings, THC and CBD monotherapy do not appear to generate alarming rates of serious adverse events in adults over 50. It also raises a clinically relevant signal that THC:CBD combination products may carry a different risk profile, particularly in oncology populations where disease progression, opioid co-administration, and cachexia all confound interpretation. However, the evidence does not support telling patients that cannabinoids have been demonstrated to be safe for their age group. It supports only a more modest claim: that no red flags have emerged from observational data, which is a necessary but insufficient condition for establishing safety.

Clinicians should be especially attentive to drug-interaction potential. Both THC and CBD undergo hepatic metabolism through cytochrome P450 pathways, with CBD acting as a potent inhibitor of CYP3A4 and CYP2D6, enzymes responsible for metabolizing many medications commonly prescribed to older adults including statins, anticoagulants, and antidepressants. The practical takeaway for clinicians today is not a change in prescribing but a reinforcement of existing best practice: before initiating any cannabinoid in a patient over 50, conduct a thorough medication reconciliation and establish a monitoring plan that includes follow-up within two to four weeks of initiation.

Study at a Glance

Study Type

Systematic review and meta-analysis of open-label trials and observational studies (no comparator arms)

Population

Adults aged 50 and over (mean age 63.19 years; 53.86% men) across diverse clinical conditions

Intervention

THC monotherapy (23 studies), CBD monotherapy (6 studies), THC:CBD combination (9 studies)

Comparator

None; all included studies were uncontrolled

Primary Outcomes

Incidence rates of adverse events, serious adverse events, and study withdrawals

Sample Size

N = 2,341 across 38 studies

Journal

Drugs & Aging

Year

2021

DOI or PMID

PROSPERO registration: CRD42019148869

Funding Source

Not specified in analysis

What Kind of Evidence Is This

This is a pre-registered systematic review and meta-analysis conducted according to PRISMA guidelines, pooling incidence rate data from uncontrolled studies. As a synthesis of open-label trials, case series, and prospective cohorts without comparator arms, it occupies a position below meta-analyses of randomized controlled trials in the evidence hierarchy. The single most important inference constraint is that without control conditions in any of the 38 primary studies, it is impossible to determine whether observed adverse events were caused by cannabinoids, by the diseases being treated, or by concurrent therapies.

How This Fits With the Broader Literature

The findings are broadly consistent with the companion meta-analysis of randomized controlled trials by the same research group (Velayudhan et al., reference 37 in the original publication), which also found that cannabinoids did not appear to produce excess serious adverse events in older populations when compared to placebo. The signal of higher withdrawal rates for THC:CBD combination products, especially in cancer settings, aligns with earlier observational work on nabiximols (Sativex) in advanced cancer pain, where tolerability has been a recurring concern. However, the current review extends the literature by explicitly synthesizing uncontrolled data that RCT-focused reviews necessarily exclude, capturing a broader slice of real-world clinical experience while inheriting the inferential limitations of that study design.

Common Misreadings

The most likely overinterpretation is reading the headline finding of “generally safe” as meaning that cannabinoid safety in older adults has been established. It has not. What has been established is that in a heterogeneous collection of uncontrolled studies, serious adverse event rates were low for THC and CBD monotherapy. Without a control group, there is no way to know what the adverse event rate would have been without cannabinoids. The wide confidence intervals and high heterogeneity across studies further limit how precisely these incidence rates should be interpreted. Citing this review as evidence that cannabinoids are “safe for older adults” would substantially exceed what the data support.

Bottom Line

This meta-analysis provides a useful descriptive baseline suggesting that THC and CBD monotherapy are tolerated by many adults over 50 without frequent serious adverse events. It does not establish that cannabinoids are safe in this population, because the absence of control groups in all included studies prevents causal attribution. Clinicians can use this review to inform risk discussions with patients, but not to justify changes in prescribing practice absent stronger controlled evidence.

References

1. Velayudhan L, McGoohan K, Sauer S. Safety and tolerability of cannabinoid-based medications in older adults: a systematic review and meta-analysis of open-label and observational studies. Drugs & Aging. 2021. PROSPERO registration: CRD42019148869.
2. Velayudhan L, et al. Cannabinoid-based medications in older adults: a meta-analysis of randomised controlled trials (companion RCT meta-analysis referenced as reference 37 in original publication).